SCHOOL OF MEDICINE

Department of Medicine

IU Liver Research

Alcoholic Hepatitis

 

Naga Chalasani, MD
Suthat Liangpunsakul, MD
Raj Vuppalanchi, MD
Relevant Investigators
 


 


Alcoholic Hepatitis team
 

Alcoholic Hepatitis is a reaction of the liver to years of heavy drinking. It may cause a spectrum of problems, ranging from mild abnormalities in liver tests to serious illness requiring hospitalization and a substantial risk of death.


The studies below are all part of the Translational Research and Evolving Alcoholic Hepatitis Treatment consortium. For more information, visit their website

Current studies:

TREAT 002: Intercept Moderately Severe Alcoholic Hepatitis
Enrolling: Yes
Duration: 6 months
Primary Outcomes measured: Change in MELD score at 6 months; incidence of serious adverse events
Drug(s): obeticholic acid table or placebo

Contact information:
Jennifer Lehman
317-278-1872
jgeck@iu.edu


TREAT 003: Immuron Severe Alcoholic Hepatitis
Enrolling: Yes
Duration: 6 months
Primary Outcomes measured: Greater decrease in mean ciculating levels in those receiving Steroids+ Imm 124-E compared to steroids + placebo
Drug(s): IMM123-E(Bovine Colostrum Drug Substance or BCDS) or Placebo

Contact information:
Jennifer Lehman
317-278-1872
jgeck@iu.edu


An Open-label, Cohort Dose Escalation Study to Assess the Safety and Efficacy Signals of F-652 in Patients with Alcoholic Hepatitis
Enrolling: No
Duration: Study drug infusions on days 1 and 7, follow-up phase day 8 to 42
Primary Outcomes measured: Absence of unexpected serious adverse events
Drug(s): F-652 infusion, 10 μg/kg, 30 μg/kg or 45 μg/kg

Contact information:
Jennifer Lehman
317-278-1872
jgeck@iu.edu

 


TREAT 001: Alcohol Hepatitis Observational Study
Enrolling: No
Duration: 1 year
Primary Outcomes measured: Developing a repository of biological samples from AH patients and heavy drinking controls

Contact information:
Jennifer Lehman
317-278-1872
jgeck@iu.edu